ClinicalTrials.gg

TargetBeta

FOLR1

folate receptor alpha · also FRα, FOLR · Folate receptors

7 programs in company-led studies act on FOLR1, from 5 companies: 4 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
rinatabart sesutecanruleGenmabphase 399 running–NCIt
mirvetuximab soravtansineruleAbbViephase 3158 running–NCIt
torvutatug samrotecanAstraZenecaphase 355 running–a judged reading
sofetabart mipitecanEli Lillyphase 322 running–a judged reading
opugotamig olatansineAbbViephase 222 running–the company's pipeline
Anti-Folate Receptor Alpha Antibody-drug Conjugate ABBV-901AbbViephase 111 running–the company's pipeline
Anti-FRa/Anti-CD3 Bispecific TCE NTB-928ruleTeneoSevenphase 111 runningCD3ENCIt

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.